<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">seamed</journal-id><journal-title-group><journal-title xml:lang="ru">Морская медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Marine Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2413-5747</issn><issn pub-type="epub">2587-7828</issn><publisher><publisher-name>Research Institute of Industrial and Maritime Medicine of the Federal Medical and Biological Agency</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.67821/2413-5747-2026-12-3-134-142</article-id><article-id custom-type="edn" pub-id-type="custom">WCUDHI</article-id><article-id custom-type="elpub" pub-id-type="custom">seamed-1017</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles</subject></subj-group></article-categories><title-group><article-title>Кардиометаболические маркеры и нарушения ритма при СД 2-го типа: ретроспективное исследование</article-title><trans-title-group xml:lang="en"><trans-title>Cardiometabolic markers and rhythm disorders in type 2 diabetes: retrospective study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2033-9610</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Однокол</surname><given-names>П. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Odnokol</surname><given-names>P. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Однокол Полина Олеговна – курсант 6-го курса, 4-го факультета</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, д. 6</p></bio><bio xml:lang="en"><p>Polina O. Odnokol – 6th year cadet of the 4th faculty</p><p>194044, Saint Petersburg, Academician Lebedev Str., 6</p></bio><email xlink:type="simple">odnokol.polina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7598-4855</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тришкин</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Trishkin</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тришкин Макар Алексеевич – курсант 5-го курса, 3-го факультета</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, д. 6</p></bio><bio xml:lang="en"><p>Makar A. Trishkin – 5th year cadet of the 3rd faculty</p><p>194044, Saint Petersburg, Academician Lebedev Str., 6</p></bio><email xlink:type="simple">hoizidcfpv@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6489-9938</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутелев</surname><given-names>Г. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutelev</surname><given-names>G. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кутелев Геннадий Геннадьевич – доктор медицинских наук, профессор кафедры военно-морской терапии</p><p>194044, Санкт-Петербург, ул. Академика Лебедева, д. 6</p></bio><bio xml:lang="en"><p>Gennady G. Kutelev – Dr. of Sci. (Med.), Professor of the Department of Naval Therapy</p><p>194044, Saint Petersburg, Academician Lebedev Str., 6</p></bio><email xlink:type="simple">gena08@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5523-8233</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пугачёв</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Pugachev</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пугачёв Максим Игоревич – кандидат медицинских наук, доцент кафедры терапии неотложных состояний</p><p>107392, Москва, ул. Малая Черкизовская, д. 7</p></bio><bio xml:lang="en"><p>Maxim I.Pugachev – Cand. of Sci. (Med.),Associate Professor of the Department of Emergency</p><p>107392, Moscow, Malaya Cherkizovskaya Str., 7</p></bio><email xlink:type="simple">kenig.max@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Военно-медицинская академия имени С. М. Кирова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Military Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Филиал Военно-медицинской академии имени С. М. Кирова в г. Москве</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Branch of the Military Medical Academy in Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2026</year></pub-date><volume>12</volume><issue>3</issue><fpage>134</fpage><lpage>142</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Однокол П.О., Тришкин М.А., Кутелев Г.Г., Пугачёв М.И., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Однокол П.О., Тришкин М.А., Кутелев Г.Г., Пугачёв М.И.</copyright-holder><copyright-holder xml:lang="en">Odnokol P.O., Trishkin M.A., Kutelev G.G., Pugachev M.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://seamed.elpub.ru/jour/article/view/1017">https://seamed.elpub.ru/jour/article/view/1017</self-uri><abstract><p>ВВЕДЕНИЕ. Сахарный диабет 2-го типа (СД 2-го типа) является значимой медико-социальной проблемой и одним из ведущих факторов риска сердечно-сосудистых осложнений (ССО), включая нарушения сердечного ритма и проводимости различного генеза. ЦЕЛЬ. Изучить связь между метаболическими нарушениями при СД 2-го типа и формированием электрофизиологических изменений миокарда.МАТЕРИАЛЫ И МЕТОДЫ. В ретроспективное исследование включены 80 пациентов мужского и женского пола в возрасте от 35 до 80 лет с установленным диагнозом СД 2-го типа. Группу сравнения составили 40 пациентов сопоставимого возраста без признаков СД 2-го типа. Всем участникам проводилось комплексное клинико-лабораторное и инструментальное обследование, включающее оценку показателей общего анализа крови (ОАК), биохимического анализа крови (БАК), электрокардиографию (ЭКГ), суточное мониторирование ЭКГ (СМЭКГ) и эхокардиографию (ЭХОКГ).РЕЗУЛЬТАТЫ. У пациентов СД 2-го типа, в отличие от группы сравнения, выявлены статистически значимые изменения показателей общего анализа крови, отражающие воспалительные и гемостатические сдвиги. Уровень лейкоцитов оказался выше (p = 0,001) при одновременном снижении гемоглобина (p = 0,012). Также отмечено повышение уровня тромбоцитов (p = 0,006) и увеличение скорости оседания эритроцитов (p &lt; 0,001), что свидетельствует о хроническом субклиническом воспалении и протромботическом состоянии. Дополнительно выявлены изменения биохимических показателей: уровень триглицеридов составил 1,85 [1,34–2,99] ммоль/л против 1,20 [0,98–1,78] ммоль/л (p &lt; 0,001), соответственно липопротеидов очень низкой плотности — 0,90 [0,60–1,33] ммоль/л и 0,54 [0,40–0,94] ммоль/л (p &lt; 0,001), фибриногена — 4,60 [3,81–5,25] г/л и 3,78 [3,22–4,36] г/л (p = 0,0011). По данным ЭХОКГ выявлены различия: фракция выброса левого желудочка составила 60,1 [55,75–64,03] % против 65,0 [62,25–67,75] % (p &lt; 0,001), диаметр легочной артерии — 2,22 [2,03–2,36] см и 2,00 [1,92–2,10] см соответственно (p &lt; 0,001).ЗАКЛЮЧЕНИЕ. СД 2-го типа сопровождается комплексом взаимосвязанных метаболических, воспалительных и гемостазиологических нарушений, сочетающихся со структурно-функциональными изменениями сердечно-сосудистой системы, включая снижение сократительной функции миокарда и признаки ремоделирования. Эти изменения соответствуют представлениям о диабетической кардиомиопатии как самостоятельном варианте поражения миокарда и создают условия для электрической нестабильности, развития нарушений ритма и повышения риска сердечно-сосудистых осложнений.</p></abstract><trans-abstract xml:lang="en"><p>INTRODUCTION. Type 2 diabetes (T2D) is a significant medical and social problem and one of the leading risk factors for cardiovascular complications (CVC), including cardiac arrhythmias and conduction disorders of various origins.OBJECTIVE. To study the relationship between metabolic disorders in T2D and the formation of electrophysiological changes in the myocardium.MATERIALS AND METHODS. This retrospective study included 80 male and female patients aged 35 to 80 years with the T2D diagnosis. The comparison group consisted of 40 age-matched patients without T2D signs. All participants underwent a comprehensive clinical, laboratory, and instrumental examination, including a complete blood count (CBC), blood chemistry panel (BCP), electrocardiography (ECG), 24-hour ECG monitoring (MECG), and echocardiography (ECHO).REULTS. Statistically significant changes in complete blood count parameters were observed in patients with T2D, in contrast to the comparison group, reflecting inflammatory and hemostatic shifts. Leukocyte levels were higher (p = 0.001) with a simultaneous decrease in hemoglobin (p = 0.012). An increase in platelet levels (p = 0.006) and an increase in the erythrocyte sedimentation rate (p &lt; 0.001) were also noted, indicating chronic subclinical inflammation and a prothrombotic state. Additionally, changes in biochemical parameters were revealed: the level of triglycerides was 1.85 [1.34–2.99] mmol/l versus 1.20 [0.98–1.78] mmol/l (p &lt; 0.001), respectively, very low density lipoproteins were 0.90 [0.60–1.33] mmol/l and 0.54 [0.40–0.94] mmol/l (p &lt; 0.001), fibrinogen was 4.60 [3.81–5.25] g/l and 3.78 [3.22–4.36] g/l (p = 0.0011). According to echocardiography data, differences were revealed: the left ventricular ejection fraction was 60.1 [55.75–64.03] % versus 65.0 [62.25–67.75] % (p &lt; 0.001), the pulmonary artery diameter was 2.22 [2.03–2.36] cm and 2.00 [1.92–2.10] cm, respectively (p &lt; 0.001).COCNLUSION. T2D is accompanied by a complex of interrelated metabolic, inflammatory, and hemostasis disorders, combined with structural and functional changes in the cardiovascular system, including decreased myocardial contractility and signs of remodeling. These changes are consistent with the concept of diabetic cardiomyopathy as an independent form of myocardial damage and create conditions for electrical instability, the development of rhythm disturbances and an increased risk of cardiovascular complications.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>морская медицина</kwd><kwd>сахарный диабет 2-го типа</kwd><kwd>нарушения сердечного ритма</kwd><kwd>сердечно-сосудистые осложнения</kwd><kwd>диабетическая кардиомиопатия</kwd><kwd>хроническое субклиническое воспаление</kwd><kwd>дислипидемия</kwd><kwd>гипергликемия</kwd><kwd>инсулинорезистентность</kwd><kwd>гемостаз</kwd><kwd>эхокардиография</kwd><kwd>фракция выброса левого желудочка</kwd><kwd>кардиометаболический риск</kwd><kwd>ренин-ангиотензиновая система</kwd></kwd-group><kwd-group xml:lang="en"><kwd>marine medicine</kwd><kwd>maritime medicine</kwd><kwd>type 2 diabetes</kwd><kwd>cardiac arrhythmias</kwd><kwd>cardiovascular complications</kwd><kwd>diabetic cardiomyopathy</kwd><kwd>chronic subclinical inflammation</kwd><kwd>dyslipidemia</kwd><kwd>hyperglycemia</kwd><kwd>insulin resistance</kwd><kwd>hemostasis</kwd><kwd>echocardiography</kwd><kwd>left ventricular ejection fraction</kwd><kwd>cardiometabolic risk</kwd><kwd>renin-angiotensin system</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ушанова Ф. О., Измайлова М. Я., Надыбина М. Н. Нарушения сердечного ритма у пациентов с сахарным диабетом 2 типа // FOCUS. Эндокринология. 2024. Т. 5, № 2. С. 12–19</mixed-citation><mixed-citation xml:lang="en">Ushanova F. O., Izmailova M. Ya., Nadybina M. N. Heart rhythm disturbances in patients with type 2 diabetes mellitus. FOCUS. Endocrinology, 2024, Vol. 5, No. 2, pp. 12–19 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rawshani A., Rawshani A., Franzén S., et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 2018, Vol. 379, No. 7, pp. 633–644. doi: 10.1056/NEJMoa1800256.</mixed-citation><mixed-citation xml:lang="en">Rawshani A., Rawshani A., Franzén S., et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med, 2018, Vol. 379, No. 7, pp. 633–644. doi: 10.1056/NEJMoa1800256.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ormazabal V., Nair S., Elfeky O., Aguayo C., Salomon C., Zuñiga F.A. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol, 2018, Vol. 17, No. 1, pp. 122. doi: 10.1186/s12933-018-0762-4.</mixed-citation><mixed-citation xml:lang="en">Ormazabal V., Nair S., Elfeky O., Aguayo C., Salomon C., Zuñiga F.A. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol, 2018, Vol. 17, No. 1, pp. 122. doi: 10.1186/s12933-018-0762-4.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gkrania-Klotsas E., Ye Z., Cooper A. J., et al. Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies. PLoS One, 2010, Vol. 5, No. 10, pp. e13405. doi: 10.1371/journal.pone.0013405.</mixed-citation><mixed-citation xml:lang="en">Gkrania-Klotsas E., Ye Z., Cooper A. J., et al. Differential White Blood Cell Count and Type 2 Diabetes: Systematic Review and Meta-Analysis of Cross-Sectional and Prospective Studies. PLoS One, 2010, Vol. 5, No. 10, pp. e13405. doi: 10.1371/journal.pone.0013405.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jannat F., Riaz M., Khan M., et al. Anemia in Patients with Type 2 Diabetes Mellitus: Pathophysiology and Clinical Implications. Clin Diabetol, 2023, Vol. 12, No. 3, pp. 201–208. doi: 10.5603/DK.a2023.0012.</mixed-citation><mixed-citation xml:lang="en">Jannat F., Riaz M., Khan M., et al. Anemia in Patients with Type 2 Diabetes Mellitus: Pathophysiology and Clinical Implications. Clin Diabetol, 2023, Vol. 12, No. 3, pp. 201–208. doi: 10.5603/DK.a2023.0012.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Mertens I., Van Gaal L. F. Mechanisms Linking Obesity and Cardiovascular Disease. Nature, 2006, Vol. 444, pp. 875–880. doi: 10.1038/nature05487.</mixed-citation><mixed-citation xml:lang="en">Mertens I., Van Gaal L. F. Mechanisms Linking Obesity and Cardiovascular Disease. Nature, 2006, Vol. 444, pp. 875–880. doi: 10.1038/nature05487.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">German Diabetes Study Group. Platelet Activation and Cardiovascular Risk in Patients with Type 2 Diabetes. Diabetes Care, 2014, Vol. 37, No. 8, pp. 2326–2334. doi: 10.2337/dc13-2456.</mixed-citation><mixed-citation xml:lang="en">German Diabetes Study Group. Platelet Activation and Cardiovascular Risk in Patients with Type 2 Diabetes. Diabetes Care, 2014, Vol. 37, No. 8, pp. 2326–2334. doi: 10.2337/dc13-2456.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Morton J. I., Zoungas S., Li Q., et al. Low HDL Cholesterol and Microvascular Complications in Type 2 Diabetes: The ADVANCE Study. Diabetologia, 2012, Vol. 55, No. 8, pp. 2241–2249. doi: 10.1007/s00125-012-2561-0.</mixed-citation><mixed-citation xml:lang="en">Morton J. I., Zoungas S., Li Q., et al. Low HDL Cholesterol and Microvascular Complications in Type 2 Diabetes: The ADVANCE Study. Diabetologia, 2012, Vol. 55, No. 8, pp. 2241–2249. doi: 10.1007/s00125-012-2561-0.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Taskinen M. R. Diabetic Dyslipidemia: From Basic Research to Clinical Practice. Diabetologia, 2003, Vol. 46, pp. 733–749. doi: 10.1007/s00125-003-1111-y.</mixed-citation><mixed-citation xml:lang="en">Taskinen M. R. Diabetic Dyslipidemia: From Basic Research to Clinical Practice. Diabetologia, 2003, Vol. 46, pp. 733–749. doi: 10.1007/s00125-003-1111-y.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jia G., Hill M. A., Sowers J. R. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res, 2018, Vol. 122, No. 4, pp. 624–638. doi: 10.1161/CIRCRESAHA.117.311586.</mixed-citation><mixed-citation xml:lang="en">Jia G., Hill M. A., Sowers J. R. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res, 2018, Vol. 122, No. 4, pp. 624–638. doi: 10.1161/CIRCRESAHA.117.311586.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Paulus W. J., Tschöpe C. A Novel Paradigm for Heart Failure with Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction. J Am Coll Cardiol, 2013, Vol. 62, No. 4, pp. 263–271. doi: 10.1016/j.jacc.2013.02.092.</mixed-citation><mixed-citation xml:lang="en">Paulus W. J., Tschöpe C. A Novel Paradigm for Heart Failure with Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction. J Am Coll Cardiol, 2013, Vol. 62, No. 4, pp. 263–271. doi: 10.1016/j.jacc.2013.02.092.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kannel W. B., Benjamin E. J. Status of the Epidemiology of Atrial Fibrillation. Med Clin North Am, 2008, Vol. 92, No. 1, pp. 17–40. doi: 10.1016/j.mcna.2007.09.002.</mixed-citation><mixed-citation xml:lang="en">Kannel W. B., Benjamin E. J. Status of the Epidemiology of Atrial Fibrillation. Med Clin North Am, 2008, Vol. 92, No. 1, pp. 17–40. doi: 10.1016/j.mcna.2007.09.002.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Huxley R. R., Filion K. B., Konety S., Alonso A. Meta-analysis of Cohort and Case-Control Studies of Type 2 Diabetes Mellitus and Risk of Atrial Fibrillation. Am J Cardiol, 2011, Vol. 108, No. 1, pp. 56–62. doi: 10.1016/j.amjcard.2011.03.004.</mixed-citation><mixed-citation xml:lang="en">Huxley R. R., Filion K. B., Konety S., Alonso A. Meta-analysis of Cohort and Case-Control Studies of Type 2 Diabetes Mellitus and Risk of Atrial Fibrillation. Am J Cardiol, 2011, Vol. 108, No. 1, pp. 56–62. doi: 10.1016/j.amjcard.2011.03.004.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sowers J. R., Epstein M., Frohlich E. D. Diabetes, Hypertension, and Cardiovascular Disease: An Update. Hypertension, 2001, Vol. 37, pp. 1053–1059. doi: 10.1161/01.HYP.37.4.1053.</mixed-citation><mixed-citation xml:lang="en">Sowers J. R., Epstein M., Frohlich E. D. Diabetes, Hypertension, and Cardiovascular Disease: An Update. Hypertension, 2001, Vol. 37, pp. 1053–1059. doi: 10.1161/01.HYP.37.4.1053.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Brownlee M. The Pathobiology of Diabetic Complications: A Unifying Mechanism. Diabetes, 2005, Vol. 54, No. 6, pp. 1615–1625. doi: 10.2337/diabetes.54.6.1615.</mixed-citation><mixed-citation xml:lang="en">Brownlee M. The Pathobiology of Diabetic Complications: A Unifying Mechanism. Diabetes, 2005, Vol. 54, No. 6, pp. 1615–1625. doi: 10.2337/diabetes.54.6.1615.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
